

THE SENATE
THE THIRTIETH LEGISLATURE
REGULAR SESSION OF 2020

COMMITTEE ON COMMERCE, CONSUMER PROTECTION, AND HEALTH

Senator Rosalyn H. Baker, Chair
Senator Stanley Chang, Vice-Chair

MEASURES DEFERRED TO FRIDAY, MARCH 13, 2020

DATE: Friday, March 13, 2020
TIME: 9:30 AM
PLACE: Conference Room 229
State Capitol
415 South Beretania Street

DECISION MAKING ON THE FOLLOWING MEASURE(S):

HB1637 HD1 (HSCR912-20) Status and Testimony	RELATING TO HEALTH. Repeals the ceiling for using moneys in the civil monetary penalty special fund by DOH for compliance activities approved by the Centers for Medicare and Medicaid Services. Appropriates funds to DOH for the establishment of a medicare administrator position. Effective 7/1/2050. (HD1)	CPH, WAM
HB1659 HD3 (HSCR995-20) Status and Testimony	RELATING TO HEALTH. Authorizes a pharmacy to provide a customized patient medication package to any person upon consent, with a valid prescription, and in compliance with labeling and dispensing requirements. Effective 07/01/2050. (HD3)	CPH
HB2097 HD2 (HSCR948-20) Status and Testimony	RELATING TO MEDICAL CANNABIS. Allows for a process to remediate any batch of cannabis or manufactured cannabis product that fails laboratory testing standards so long as any final cannabis or manufactured cannabis product passes all the laboratory standards. Authorizes licensed dispensaries to manufacture and distribute edible cannabis products, under certain conditions, and circulate, sponsor, and promote educational and scientific information and events related to cannabis. Effective 7/1/2050. (HD2)	CPH, JDC

[HB2102 HD1](#)
[\(HSCR700-20\)](#)
[Status and Testimony](#)

RELATING TO HEMP PRODUCTS.
Requires labels on hemp products. Prohibits unwarranted health-related statements about hemp products. Establishes standards for hemp product manufacturers. Prohibits the manufacture or sale of any food into which a hemp product has been added. Prohibits the sale of hemp products designed to appeal to children. Establishes that a product shall not be considered adulterated or misbranded solely by the inclusion of hemp with certain exceptions. Clarifies that a licensed medical cannabis dispensary is not prohibited from manufacturing, distributing, or selling products that contain hemp, or cannabinoids, extracts, or derivatives from hemp, subject to certain conditions. Prohibits the sale of hemp products to persons under twenty-one years of age. Requires DOH to report to the legislature. Effective 7/1/2050. Sunsets 6/30/2023. (HD1)

CPH, JDC/WAM

[HB1805 HD1](#)
[\(HSCR789-20\)](#)
[Status and Testimony](#)

RELATING TO PRESCRIPTION DRUGS.
Requires prescription drug manufacturers to notify prescription drug benefit plans and pharmacy benefit managers if a proposed increase in the wholesale acquisition cost of certain drugs would result in a percentage increase of ten per cent or more than the percentage change in the Consumer Price Index over a two year period. Requires the drug manufacturer to identify and report to the insurance commissioner information on certain drugs whose wholesale acquisition cost increases by a certain amount during a specified time frame. Effective 7/1/2050. (HD1)

CPH

[HB2340 HD2](#)
[\(HSCR923-20\)](#)
[Status and Testimony](#)

RELATING TO DEAD BODIES.
Clarifies prohibited actions related to anatomical gifts and disposition of bodies. Effective 7/1/2050. (HD2)

CPH, JDC

No testimony will be accepted.

FOR AMENDED NOTICES: Measures that have been deleted are stricken through and measures that have been added are underscored. If a measure is both underscored and stricken through, that measure has been deleted from the agenda.

FOR FURTHER INFORMATION, PLEASE CONTACT THE COMMITTEE CLERK AT 808-586-6070.